299 related articles for article (PubMed ID: 32248831)
41. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
Guémy C; Laforêt P
Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019
[TBL] [Abstract][Full Text] [Related]
42. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
43. Screening for late-onset Pompe disease in Internal Medicine departments in Spain.
López-Rodríguez M; Torralba-Cabeza MA; de Pedro IP; Rivera A; Gil RS; Gómez-Belda A; de la Peña JLP; de Los Santos Moreno A; Selva-O'Callaghan A; Gárate IG; García AG; Hurtado R; de Ureta PT; Barba-Romero MÁ; Milisenda JC; Grau-Junyent JM;
Orphanet J Rare Dis; 2023 Aug; 18(1):256. PubMed ID: 37653444
[TBL] [Abstract][Full Text] [Related]
44. Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).
Yamauchi M; Nakayama H; Shiota S; Ohshima Y; Terada J; Nishijima T; Kosuga M; Kitamura T; Tachibana N; Oguri T; Shirahama R; Aoki Y; Ishigaki K; Sugie K; Yagi T; Muraki H; Fujita Y; Takatani T; Muro S
Sleep Breath; 2021 Jun; 25(2):695-704. PubMed ID: 32808237
[TBL] [Abstract][Full Text] [Related]
45. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
Witkowski G; Konopko M; Rola R; Ługowska A; Ryglewicz D; Sienkiewicz-Jarosz H
Neurol Neurochir Pol; 2018 Aug; 52(4):465-469. PubMed ID: 29803406
[TBL] [Abstract][Full Text] [Related]
46. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
Lessard LER; Tard C; Salort-Campana E; Sacconi S; Béhin A; Bassez G; Orlikowski D; Merle P; Nollet S; Gallay L; Bérard F; Robinson P; Bouhour F; Laforêt P
Mol Genet Metab; 2023 Jul; 139(3):107611. PubMed ID: 37285781
[TBL] [Abstract][Full Text] [Related]
47. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS
Kishnani PS; Shohet S; Raza S; Hummel N; Castelli JP; Sitaraman Das S; Jiang H; Kopiec A; Keyzor I; Hahn A
J Patient Rep Outcomes; 2024 Jan; 8(1):13. PubMed ID: 38294575
[TBL] [Abstract][Full Text] [Related]
48. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
[TBL] [Abstract][Full Text] [Related]
49. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
[TBL] [Abstract][Full Text] [Related]
50. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ].
Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L
Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692
[No Abstract] [Full Text] [Related]
51. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
[TBL] [Abstract][Full Text] [Related]
52. Toward deconstructing the phenotype of late-onset Pompe disease.
Schüller A; Wenninger S; Strigl-Pill N; Schoser B
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):80-8. PubMed ID: 22253010
[TBL] [Abstract][Full Text] [Related]
53. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
[TBL] [Abstract][Full Text] [Related]
54. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy.
Golsari A; Nasimzadah A; Thomalla G; Keller S; Gerloff C; Magnus T
Neuromuscul Disord; 2018 Mar; 28(3):257-261. PubMed ID: 29326002
[TBL] [Abstract][Full Text] [Related]
56. Screening for late-onset Pompe disease in Poland.
Jastrzębska A; Potulska-Chromik A; Łusakowska A; Jastrzębski M; Lipowska M; Kierdaszuk B; Kamińska A; Kostera-Pruszczyk A
Acta Neurol Scand; 2019 Oct; 140(4):239-243. PubMed ID: 31125121
[TBL] [Abstract][Full Text] [Related]
57. Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.
Lefeuvre C; De Antonio M; Bouhour F; Tard C; Salort-Campana E; Lagrange E; Behin A; Sole G; Noury JB; Sacconi S; Magot A; Nadaj-Pakleza A; Lacour A; Beltran S; Spinazzi M; Cintas P; Renard D; Michaud M; Bedat-Millet AL; Prigent H; Taouagh N; Arrassi A; Hamroun D; Attarian S; Laforêt P;
Neurology; 2023 Aug; 101(9):e966-e977. PubMed ID: 37419682
[TBL] [Abstract][Full Text] [Related]
58. Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease.
Ruggeri P; Lo Monaco L; Musumeci O; Tavilla G; Gaeta M; Caramori G; Toscano A
Neurol Sci; 2020 Aug; 41(8):2175-2184. PubMed ID: 32162165
[TBL] [Abstract][Full Text] [Related]
59. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
[TBL] [Abstract][Full Text] [Related]
60. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis.
Musumeci O; Marino S; Granata F; Morabito R; Bonanno L; Brizzi T; Lo Buono V; Corallo F; Longo M; Toscano A
Eur J Neurol; 2019 Mar; 26(3):442-e35. PubMed ID: 30312517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
